Axogen Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	no data
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	less than a year
Gemiddelde ambtstermijn bestuur	3.8yrs

Recente managementupdates

Recent updates

CEO

Axogen heeft geen CEO, of we hebben geen gegevens over hen.

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Nir Naor	Chief Financial Officer	less than a year	US$509.68k	geen gegevens
Karen Zaderej	Advisor	less than a year	US$5.53m	2.6% $ 15.4m
Erick DeVinney	Chief Innovation Officer	less than a year	US$1.51m	0.30% $ 1.8m
Todd Puckett	Vice President of Operations	less than a year	geen gegevens	geen gegevens
Harold Tamayo	Vice President of Finance & Investor Relations	no data	geen gegevens	geen gegevens
Marc Began	Executive VP	1.7yrs	geen gegevens	geen gegevens
Doris Quackenbush	Vice President of Sales	2.8yrs	geen gegevens	geen gegevens
Jens Kemp	Chief Marketing Officer	1.8yrs	geen gegevens	geen gegevens
Ivica Ducic	Chief Medical Officer	less than a year	geen gegevens	geen gegevens

0.9yrs

Gemiddelde duur

52.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 0HKD wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.9 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Paul Thomas	Independent Director	4.2yrs	US$220.00k	0.049% $ 288.2k
Guido Neels	Independent Director	9.3yrs	US$217.50k	0.18% $ 1.1m
Bruce Mast	Member of Board of Advisor	no data	geen gegevens	geen gegevens
David Muir	Member of Board of Advisor	no data	geen gegevens	geen gegevens
John Johnson	Independent Director	3.3yrs	US$215.00k	0.042% $ 247.4k
Kathy Weiler	Independent Director	less than a year	US$293.37k	geen gegevens
Alan Levine	Independent Director	5.5yrs	US$217.50k	0.069% $ 406.3k
Amy Wendell	Independent Lead Director	8.2yrs	US$255.00k	0.18% $ 1.1m
William Burke	Independent Director	2.3yrs	US$220.00k	0.063% $ 375.9k
Joseph Tyndall	Independent Director	1.9yrs	US$205.00k	0.051% $ 303.9k

3.8yrs

Gemiddelde duur

60yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 0HKD wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).

Axogen Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Axogen, Inc. Announces Chief Executive Officer Changes

AxoGen, Inc., Annual General Meeting, Jun 05, 2024

AxoGen, Inc. Announces Executive Changes

Vice President of Operations recently sold US$320k worth of stock

Axogen, Inc. Appoints Kathy Weiler to its Board of Directors

Insider recently sold US$94k worth of stock

Recent updates

Third quarter 2024 earnings released: US$0.042 loss per share (vs US$0.095 loss in 3Q 2023)

Axogen, Inc. Maintains Earnings Guidance for 2024

No longer forecast to breakeven

Axogen, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Axogen, Inc. Announces Chief Executive Officer Changes

New minor risk - Profitability

Second quarter 2024 earnings released: US$0.044 loss per share (vs US$0.15 loss in 2Q 2023)

New major risk - Share price stability

AxoGen, Inc. Updates Earnings Guidance for the Full Year 2024

AxoGen, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Forecast breakeven date pushed back to 2026

Axogen, Inc. Announces Full Launch of Avive+ Soft Tissue Matrix

Forecast breakeven date moved forward to 2025

Axogen, Inc. Provides Revenue Guidance for the Year 2024

New minor risk - Financial position

Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix

AxoGen, Inc., Annual General Meeting, Jun 05, 2024

AxoGen, Inc. to Report Q1, 2024 Results on May 02, 2024

New minor risk - Shareholder dilution

AxoGen, Inc. Announces Executive Changes

Vice President of Operations recently sold US$320k worth of stock

New minor risk - Shareholder dilution

AxoGen, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Full year 2023 earnings released: US$0.51 loss per share (vs US$0.69 loss in FY 2022)

Forecast breakeven date pushed back to 2026

Axogen, Inc. Announces Positive Topline Results from Its REPOSE Clinical Study

AxoGen, Inc. to Report Q4, 2023 Final Results on Mar 05, 2024

Axogen, Inc. Appoints Kathy Weiler to its Board of Directors

Insider recently sold US$94k worth of stock

AxoGen, Inc. Announces CFO Changes

Axogen, Inc. Provides Revenue Guidance for the Full-Year 2023

Forecast to breakeven in 2025

AxoGen, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Axogen, Inc. Announces Full Launch of Axoguard HA+ Nerve Protector

Independent Director recently bought US$66k worth of stock

Independent Director recently bought US$61k worth of stock

Axogen, Inc. Provides Revenue Guidance for the Year 2023

Forecast to breakeven in 2025

AxoGen, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Director recently sold US$366k worth of stock

Director recently sold US$69k worth of stock

Director recently sold US$69k worth of stock

AxoGen, Inc. Provides Earnings Guidance for the Full-Year 2023

First quarter 2023 earnings released: US$0.17 loss per share (vs US$0.27 loss in 1Q 2022)

No longer forecast to breakeven

Axogen, Inc. Appoints Jens Schroeder Kemp as Chief Marketing Officer

Forecast to breakeven in 2025

AxoGen, Inc. to Report Q4, 2022 Results on Mar 14, 2023

Forecast to breakeven in 2025

Forecast to breakeven in 2025

AxoGen, Inc. Updates Earnings Guidance for the Full Year 2022

Axogen, Inc. Announces Directorate Changes

AxoGen, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Second quarter 2022 earnings released: US$0.18 loss per share (vs US$0.19 loss in 2Q 2021)

Eric Sandberg, Current Chief Commercial Officer Will Be Leaving AxoGen, Inc

Axogen, Inc. Appoints William Burke to Board of Directors

First quarter 2022 earnings released: US$0.27 loss per share (vs US$0.16 loss in 1Q 2021)

AxoGen, Inc. Provides Earnings Guidance for the Full Year of 2022

AxoGen, Inc., Annual General Meeting, May 25, 2022

AxoGen, Inc. to Report Q1, 2022 Results on May 04, 2022

AxoGen, Inc. Announces Board Changes

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

AxoGen, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2021

Axogen RECON(SM) Clinical Study Completes Subject Follow-up

Second quarter 2021 earnings released: US$0.19 loss per share (vs US$0.20 loss in 2Q 2020)

Chief Human Resources Officer recently sold US$50k worth of stock

First quarter 2021 earnings released: US$0.16 loss per share (vs US$0.21 loss in 1Q 2020)

AxoGen, Inc. Re-Iterates Revenue Guidance for the Full Year of Fiscal 2021

Axogen, Inc. Promotes Peter J. Mariani to Executive Vice President